Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis-Reference-Cited by-同舟云学术

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

Published:2019 Issue:1 Volume:43 Page:31
ISSN:2233-6079
Container-title:Diabetes & Metabolism Journal
language:en
Short-container-title:Diabetes Metab J

Author:

Lee Yong-ho¹²,Cho Yongin¹²,Lee Byung-Wan¹²,Park Cheol-Young³,Lee Dae Ho⁴,Cha Bong-Soo¹²,Rhee Eun-Jung³^ORCID

Affiliation:

1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

2. Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.

3. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

4. Department of Internal Medicine, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea.

Publisher

Korean Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism

Link

https://synapse.koreamed.org/pdf/10.4093/dmj.2019.0011

Reference105 articles.

1. International Diabetes Federation: IDF Diabetes Atlas: Key Messages. cited 2019 Feb 8. Available from: http://diabetesatlas.org/key-messages.html

2. Korean Diabetes Association: Diabetes Fact Sheet in Korea 2018. cited 2019 Feb 8. Available from: http://www.diabetes.or.kr/pro/news/admin.php?category=A&code=admin&number=1615&mode=view

3. NAFLD and diabetes mellitus

4. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study;Diabetes, Obesity and Metabolism;2024-09-02

2. Relationship between fibrosis-4 score and microvascular complications in patients with type 2 diabetes mellitus;Arab Journal of Gastroenterology;2024-08

3. Genetically engineered long-acting Esculentin-2CHa(1−30) fusion protein with potential applicability for the treatment of NAFLD;Journal of Controlled Release;2024-08

4. Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems;BMC Primary Care;2024-07-20

5. Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies;Internal and Emergency Medicine;2024-07-06